Status
Terminated
Phase
Phase 3
Enrollment
391
Locations
1
Results
Not posted
Publications
0
Study summary
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).
Interventions
DRUG
Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy). Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
DRUG
Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy). Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Timeline
First posted
Aug 17, 2021
Study start
Nov 1, 2021
Primary completion
Sep 6, 2024
Study completion
Sep 6, 2024
Results posted
Not reported
Registry updated
Apr 3, 2026
Outcomes
pCR rate (assessed by pathology BICR)
Time frame · 36 months since the first subject will be enrolled.
Defined as the proportion of subjects with no residual tumor detected in prostatectomy specimens by H\&E staining and ancillary immunohistochemistry (if necessary) as assessed by pathology BICR.
MFS (assessed by imaging BICR).
Time frame · 84 months since the first subject will be enrolled.
Defined as the time from the date of randomization to the date of first occurrence of BICR-confirmed radiographic distant metastasis, accidental pathologic finding of distant metastasis, or death from any cause (whichever occurs first), regardless of whether the subject reveives any other anti-tumor therapy or has missing (or unevaluable) tumor assessments.
MFS (investigator-assessed).
Time frame · 84 months since the first subject will be enrolled.
Defined as the time from the date of randomization to the date of first occurrence of investigator-assessed radiographic distant metastasis to the bone or soft tissue, accidental pathologic finding of distant metastasis, or death from any cause (whichever occurs first), regardless of subsequent anti-tumor treatment or missing (or unevaluable) tumor assessments.
PSA response rate.
Time frame · 25 months since the first subject will be enrolled.
Defined as the proportion of subjects with a ≥ 90% decrease in PSA levels from baseline on Day 1 of Cycle 4.
PSM rate.
Time frame · 31 months since the first subject will be enrolled.
Defined as the proportion of subjects without tumor cells detected in the margin of prostatectomy pathological specimens following H\&E staining and ancillary immunohistochemistry (if necessary), as assessed by local pathologists.
Time to BCR.
Time frame · 42 months since the first subject will be enrolled.
Defined as the time from the date of randomization to the time of BCR (i.e. two consecutive PSA rise ≥ 0.2 ng/mL following radical prostatectomy).
Eligibility
Inclusion Criteria: 1. Age of ≥ 18 years old; 2. ECOG PS score of 0 or 1; 3. Pathologically diagnosed as prostate adenocarcinoma; 4. High-risk patients 5. No distant metastasis (clinical staging of M0) as determined by BICR of imaging examinations; 6. Subjects who are candidates for and plan to undergo radical prostatectomy (removal of the entire prostate and seminal vesicle plus pelvic lymphadenectomy); Exclusion Criteria: 1. Subjects who received any prior treatment for prostate cancer, except medical ADT and/or first-generation androgen receptor antagonists (such as bicalutamide) for not more than 4 weeks; 2. Subjects who received any other investigational products or underwent major surgery within 4 weeks prior to randomization; 3. Subjects who are planning bilateral orchidectomy during the treatment period of the study; 4. Subjects with dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption; 5. Subjects with a history of epilepsy, or diseases that can induce seizures occurred within 12 months prior to randomization (including a history of transient ischemic attack, stroke, traumatic brain injury, and cognitive impairment, requiring hospitalization); 6. Subjects with active heart disease within 6 months prior to randomization, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment;
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Fudan University Shanghai Cancer center
Shanghai, Shanghai Municipality, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
National Cancer Institute (NCI) · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8
Phase 3
Active, not recruiting
608
2026-07
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
Washington University School of Medicine · Breast Cancer · Cancer of Breast
Phase 2
Recruiting
50
2026-07
Aristotle University Of Thessaloniki · Metabolic Dysfunction-Associated Steatotic Liver Disease · Nonalcoholic Fatty Liver
Phase 4
Active, not recruiting
62
2026-07
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
Novartis · Early Breast Cancer
Phase 3
Recruiting
1,400
2026-07
Eli Lilly · Breast Neoplasms
Phase 2
Recruiting
600
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.